Stryker stock trades near highs as orthopedic demand supports revenue growth

Stryker stock is supported by steady orthopedic and medical technology demand, with recent quarterly figures showing double-digit revenue growth and solid profitability while the company continues to invest in innovation and integration of past acquisitions.

Stryker Corp. (ISIN US8636671013) stock is supported by recent double-digit revenue growth and strong profitability in its latest reported quarter, underscoring the medical technology group’s position as a major supplier of orthopedic implants and surgical equipment. In its most recently available quarterly update for Q1 2024, Stryker reported total revenue of approximately $5.24 billion, up around 9.7% from about $4.78 billion in Q1 2023, with investors focusing on how sustained procedure volumes and hospital capital spending trends feed through to earnings and cash flow.

Revenue up 9.7 percent year on year

According to Stryker’s Q1 2024 earnings release, the company generated about $5.24 billion in net sales for the quarter, compared with roughly $4.78 billion in the same period a year earlier, representing year-on-year growth of 9.7%. The growth was driven by higher orthopedic procedure volumes, continued strength in MedSurg and Neurotechnology, and contributions from past acquisitions that have expanded Stryker’s portfolio in robotic surgery and advanced implants. Investor attention is often drawn to whether this growth rate can be sustained given hospital staffing constraints and reimbursement dynamics.

Within this total, orthopedic and spine products, including hips, knees and trauma implants, remain a substantial revenue contributor. Stryker has historically generated several billion dollars of annual orthopedic sales, and in Q1 2024 these businesses continued to benefit from deferred procedures returning and demographic trends such as aging populations in the United States, Europe and other developed markets. Alongside orthopedic implants, Stryker’s MedSurg and Neurotechnology segment, which includes surgical equipment, endoscopy, emergency medical products and neurovascular devices, also delivered growth in the mid- to high single-digit range year on year in Q1 2024, supporting the overall 9.7% revenue increase.

Margin profile and earnings support valuation

In the same Q1 2024 period, Stryker reported net earnings attributable to the company of roughly $0.96 billion, up from around $0.76 billion in Q1 2023, with diluted earnings per share rising from approximately $2.00 to about $2.50. That equates to EPS growth of roughly 25%, which outpaced the 9.7% revenue increase and indicated some operating leverage as higher sales flowed through to the bottom line. For investors assessing Stryker stock, the relationship between revenue growth, margin development and EPS remains central to valuation discussions, especially as the company invests in R&D and integration costs.

Stryker’s adjusted operating margin for Q1 2024 was around 23% of sales, roughly in line with or modestly above the prior year. Maintaining margins in the low- to mid-twenties percent range is important in the medical technology sector, where pricing pressure from hospital customers and payers can weigh on profitability. A stable or improving margin profile provides backing for Stryker’s continued investments in robotic surgery platforms, digital tools and next-generation implants, while also supporting cash generation for debt reduction and dividends.

Stryker products underpin orthopedic franchise

A key pillar of Stryker’s business is its line of orthopedic implants and related technologies, which help drive the revenue figures reported in recent quarters. The company is known for hip and knee replacement systems, trauma and extremities products, as well as spine implants and biologics. These products are used in elective and trauma procedures worldwide, and their utilization levels are closely linked to hospital operating room capacity, staffing and patient flow dynamics. As procedure volumes normalize or grow, demand for Stryker’s implants tends to follow, supporting revenue trends such as the 9.7% year-on-year increase seen in Q1 2024.

Stryker also offers surgical equipment and navigation systems that complement its implants. Its MedSurg portfolio includes operating room tables, surgical instruments, cameras and endoscopy systems, as well as emergency medical equipment like defibrillators and stretchers. Revenue from MedSurg and Neurotechnology has grown alongside orthopedic sales, providing diversification across product categories and customer types. In recent periods, the company has highlighted increased adoption of its systems in hospitals seeking to standardize equipment and improve efficiency, which can sustain recurring orders and service contracts.

Stryker stock and market metrics

Stryker stock is listed on the New York Stock Exchange, where it trades under the ticker symbol SYK. As of early 2024, the company’s equity market capitalization stood in the region of approximately $120 billion, reflecting investors’ expectations of ongoing growth in orthopedic and surgical procedures as well as continued innovation in medical technology. This market value places Stryker among the larger constituents of US healthcare indices and makes the stock a core holding in many medical technology and broad healthcare portfolios.

Over the 52-week period leading up to early 2024, Stryker shares traded in a range broadly between around $250 and $325, with the upper end of that band marking or approaching a new yearly high. The proximity of the current share price to the top of this range signals that investors have rewarded the company for its 9.7% revenue growth in Q1 2024 and approximately 25% EPS expansion over the same period compared with Q1 2023. For portfolio managers, such performance can justify a premium valuation versus some peers, although the level of that premium is continually reassessed in light of sector conditions, interest rates and hospital spending trends.

Key data on Stryker stock

• Company: Stryker Corp.
• ISIN: US8636671013
• Ticker: NYSE: SYK
• Trading venue: NYSE
• Market capitalization: around $120 billion (as of early 2024)
• Sector / Industry: Health Care / Medical Technology
• Index membership: S&P 500